CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Viela Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Viela Bio Inc
1 Medimmune Way
Phone: (240) 558-0038p:240 558-0038 Gaithersburg, MD  20878  United States Fax: (302) 636-5454f:302 636-5454

This company ceased filing statements with the SEC on 3/25/2021.
As of 10/6/2023, the Company is part of Horizon Therapeutics PLC, a subsidiary of Amgen, Inc.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Viela Bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for severe inflammation and autoimmune diseases. Its product pipeline includes Inebilizumab, VIB4920 and VIB7734. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. VIB4920 is a fusion protein designed to bind to CD40 ligand (CD40L) on activated T cells, blocking the interaction with CD40 expressed on B cells and preventing them from differentiating into plasma cells and memory B cells. VIB7734 is a treatment for autoimmune and related inflammatory diseases.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202012/31/2020YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer ZhengbinYao 54 1/1/2019 2/1/2018
Chief Financial Officer MitchellChan 39 6/1/2019 6/1/2019
Vice President - Head of Commercial WilliamRagatz 51 1/1/2019 1/1/2019
7 additional Officers and Directors records available in full report.

Business Names
Business Name
VIE
Viela Bio BV
Viela Bio GmbH

General Information
Number of Employees: 170 (As of 12/31/2020)
Outstanding Shares: 54,950,149 (As of 3/1/2021)
Stock Exchange: NASD
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, January 6, 2024